Last reviewed · How we verify
BAT2206
BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.
BAT2206 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | BAT2206 |
|---|---|
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific antibody; dual checkpoint inhibitor |
| Target | Likely PD-1 and LAG-3 (or similar dual checkpoint targets) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BAT2206 functions as a bispecific monoclonal antibody designed to target dual immune pathways, likely involving PD-1 and LAG-3 or similar checkpoint molecules. By blocking inhibitory signals on T cells through multiple mechanisms simultaneously, the drug aims to overcome tumor immune evasion more effectively than single-checkpoint inhibitors, potentially improving anti-tumor immunity in solid tumors.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT2206 CI brief — competitive landscape report
- BAT2206 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI